Johnson & Johnson (J&J), the world's biggest healthcare company, has invested $1.5 billion (Ôé¼1 billion) in Dublin, Ireland-based biopharmaceutical company Elan. J&J, whose headquarters are in New Jersey, USA, will take over ElanÔÇÖs 50 per cent stake in its Alzheimer's immunotherapy research partnership, or AIP Program, that it currently runs with pharmaceutical firm Wyeth, also based in New Jersey. J&J will set up a new company 49.9 per cent owned by Elan, with J&J gaining all rights to any medicines approved and Elan receiving 49.9 per cent of the